ClinicalTrialsFinder
RecruitingNot ApplicableNCT06492720

A Pilot Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy

A Pilot, Open-label, Two-arm, Parallel-group Randomized Trial Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy

Sponsor

NaviFUS Corporation

Enrollment

16 participants

Start Date

Sep 1, 2024

Study Type

INTERVENTIONAL

Conditions

EpilepsyDrug Resistant EpilepsyEpilepsy, Temporal LobeSeizures, Focal

Summary

This will be a prospective, pilot, open-label, two-arm, parallel-group, randomized study to evaluate the efficacy and safety of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with drug-resistant epilepsy (DRE).

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Focused ultrasound (FUS) treatment for people with drug resistant epilepsy, epilepsy, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEFocused ultrasound (FUS) treatment

The mechanism of action of FUS neuromodulation involves the activation of voltage-gated ion channels to induce temporary neuromodulation.

Locations(1)

Taipei Veterans General Hospital

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06492720

Related Trials

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

NCT075638814 locations

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures

NCT075941195 locations

Multimodal PET Imaging With 18F-FDG/SV2A/TSPO for Resection Planning in Drug-Resistant Epilepsy

NCT071473091 location

Real-World Evidence in Patient-Reported Outcomes for Medical Cannabis (MC-RWE)

NCT045260931 location

Surgery as a Treatment for Medically Intractable Epilepsy

NCT012731291 location